US 12,434,073 B2
Diffusing alpha-emitter radiation therapy for prostate cancer
Itzhak Kelson, Tel Aviv (IL); Yona Keisari, Ramat Gan (IL); Amnon Gat, Matan (IL); Robert Den, Merion Station, PA (US); Ofer Magen, Hod Hasharon (IL); Vered Domankevich, Hod Hasharon (IL); Lior Arazi, Tel Aviv (IL); Tomer Cooks, Gedera (IL); Guy Heger, Ramat Gan (IL); Mirta Dumančić, Beer Sheva (IL); Ishai Luz, Kibbutz Gevim (IL); and Maayan Hedva Vatarescu, Lehavim (IL)
Assigned to Alpha Tau Medical Ltd, Jerusalem (IL)
Filed by Alpha Tau Medical Ltd., Jerusalem (IL)
Filed on Feb. 26, 2024, as Appl. No. 18/586,598.
Application 18/586,598 is a continuation of application No. 18/094,429, filed on Jan. 9, 2023, granted, now 11,964,168.
Application 18/094,429 is a continuation of application No. PCT/IB2022/055329, filed on Jun. 8, 2022.
Application PCT/IB2022/055329 is a continuation in part of application No. 17/343,784, filed on Jun. 10, 2021, abandoned.
Prior Publication US 2024/0198132 A1, Jun. 20, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 5/10 (2006.01)
CPC A61N 5/1027 (2013.01) [A61N 2005/1024 (2013.01); A61N 2005/1085 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A method for treating a prostate cancer tumor, comprising:
identifying a tumor as a prostate cancer tumor; and
implanting in the tumor identified as a prostate cancer tumor, at least one diffusing alpha-emitter radiation therapy (DaRT) source with a suitable radon release rate and for a given duration, such that the at least one DaRT source provides during the given duration a cumulated activity of released radon between 7 Mega becquerel (MBq) hour and 14.7 MBq hour, per centimeter length,
wherein implanting the at least one DaRT source comprises implanting an array of DaRT sources, each DaRT source separated from an adjacent DaRT source in the array by less than 3.9 millimeters.